CLINICAL_TRIALS
trial_result
· 2019-05-21
Clinical Trial Update: Study of Anlotinib in Patients With Primary Malignant Bone Tumors [Phase 2]
Summary
Phase 2 clinical trial update for Anlotinib in patients with primary malignant bone tumors.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Neoplasm of Bone | Phase 2 | Status: UNKNOWN